PFO tamponade is an effective and safe vitreous substitute

Article

The perfluoro-n-octane (PFO) tamponade is a safe and effective short-term vitreous substitute in primary rhegmatogenous retinal detachment repair

The perfluoro-n-octane (PFO) tamponade is a safe and effective short-term vitreous substitute in primary rhegmatogenous retinal detachment repair, reveals a study in Retina

Dr Ryan Rush and his team, Sydney Eye Hospital, Australia, retrospectively analysed the charts of 39 eyes at 2-24 postoperative months after primary PFO retention. The second replacement was evaluated for anatomical attachment rates, visual acuity gain and postoperative complications.

The results demonstrated that 33 of 39 eyes had four or more retinal breaks - 31 of these eyes had at least one inferior break and 12 presented with preoperative proliferative vitreoretinopathy.

PFO was retained without posturing and all eyes showed full anatomical retinal attachment after primary vitrectomy for at least 7-17 days. The final anatomical success rate was 92.4% after perfluoropropane gas or siicone oil PFO exchange.

Visual acuity improved from 2.07 ± 0.86 to 0.76 ± 0.79 logarithm of the minimum angle of resolution in macula-off and 0.11 ±0.08 to 0.12 ± 0.09 logarithm of the minimum angle of resolution in macula-on rhegmatogenous retinal detachment eyes.

Posterior capsular opacification was greatly increased due to PFO retention, without affecting the final retinal attachment success rate. The highest reattachment rates were made when perfluoropropane or silicone oil was swapped for PFO.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.